Introduction
============

Bladder cancer (BCa) is a heterogeneous disease with a variable disease history. At present, BCa is the ninth most common tumor worldwide ([@b1-mmr-10-04-1746]), ranking fourth among men and ninth among women ([@b2-mmr-10-04-1746]). In the United States, \~10,400 new BCa cases emerge and 36,500 BCa-related deaths occur every year ([@b3-mmr-10-04-1746]). The diseases of urothelial carcinoma can be classified depending on their depth of invasion as: pTa (papillary), pT1 (lamina propria invasion), pT2 (muscle invasion), pT3 (invasion to peri-vesical fat) and pT4 (locally advanced).

BCa has a multifactorial etiology. Numerous studies have identified risk factors for the development of BCa and the affected cellular processes, including low-penetrance gene polymorphisms, smoking ([@b4-mmr-10-04-1746]), occupational exposure to aromatic amines and schistosomiasis infection ([@b5-mmr-10-04-1746],[@b6-mmr-10-04-1746]). In addition, the fact that men are 3--4 times more frequently affected than women indicates hormone regulation as an additional factor ([@b7-mmr-10-04-1746],[@b8-mmr-10-04-1746]).

The detection of BCa remains difficult due to the lack of specific tumor markers and the emergence of new symptoms. There is no standard therapy for patients with BCa; treatment options include surgery, chemo-, biological and radiation therapy. In addition, these methods show currently limited effectiveness, which is further reduced by the high recurrence of BCa and the high mortality deriving from increased rates of progression of the disease ([@b9-mmr-10-04-1746]). There is thus an urgent need to develop more specific and efficient diagnostic tools and therapeutic approaches to better understand and treat the onset and course of BCa.

Earlier studies have suggested that different mechanisms have evolved to respond to specific phenotype alterations in the molecular and cellular pathways involved in BCa. A number of genetic variations in major carcinogenesis-related pathways can induce BCa. For example, in healthy cells, the cell cycle is controlled by tightly linking the p53 and retinoblastoma (RB) pathways that influence regulation of apoptosis, signal transduction and gene expression. During cancer progression and metastasis, the mutated p53 protein exerts profound changes in regulatory networks involved in cell adhesion and angiogenesis, and becomes resistant to degradation in BCa of pT2--pT4 ([@b10-mmr-10-04-1746]). However, the specific mechanisms underlying the progression of BCa are still unclear, and therefore, identifying genetic markers of the disease will allow the development of effective treatment and detection methods for early-stage bladder tumors.

In the present study, we identified genes the expression of which is significantly changed between healthy and cancer cells and discuss the biological functions of these genes and the related pathways. In addition, we built a network of BCa-affected pathways in order to explore the mechanisms underlying the pathogenesis, occurrence and development of BCa. Our results may provide valuable molecular insights for BCa treatment.

Materials and methods
=====================

mRNA expression profiling data
------------------------------

The mRNA expression profiling dataset for BCa was downloaded from the Gene Expression Omnibus (GEO) database (accession no. GSE13507) at the National Center of Biotechnology Information. The dataset comprises a total of 256 samples, including 10 healthy bladder mucosae, 58 normal-looking bladder mucosae surrounding cancer, 165 primary bladder cancer and 23 recurrent non-muscle invasive tumor tissues. Gene expression was previously studied in these samples on an Illumina Human-6 v2.0 expression beadchip platform ([@b11-mmr-10-04-1746],[@b12-mmr-10-04-1746]).

Data processing
---------------

The raw expression data were downloaded as a Series Matrix file. This expression matrix contained 43,148 probes. Among these, a total of 24,995 probes uniquely mapped to 24,340 genes. For different probes mapping to the same gene, we the mean probe value was calculated for the gene expression value. An expression matrix (24,340\*234) was thus obtained, with each row representing gene expression value, and each column representing the sample. From the 256 samples, we selected 233, corresponding to 165 primary BCa and 68 control samples (healthy bladder and normal-looking bladder mucosae surrounding the cancer).

Identification of differentially expressed genes (DEGs)
-------------------------------------------------------

A statistical t-test was used to identify DEGs between BCa and control samples and to calculate the associated p-values. Multiple testing correction on these p-values was performed with the Benjamini and Hochberg method ([@b13-mmr-10-04-1746]), and provided false discovery rates (FDRs). DEGs with an FDR\<0.05 were selected for further analyses.

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis
--------------------------------------------------------------------------

KEGG is a knowledge database for the systematic analysis of gene functions, linking genomic information with high-order functional information. To identify significantly enriched KEGG pathways among the DEGs, we first downloaded from the database 232 KEGG pathways on April 26th, 2011 ([@b14-mmr-10-04-1746]). We next used a hypergeometric distribution model to test the statistical significance of the hypothesis that all pathways are co-disrupted in the same samples. The resulting P-value was calculated as follows:

p

=

1

\-

∑

0

k

\-

1

C

k

m

C

n

\-

k

N

\-

m

C

n

N

In this formula, N is the total number of gene samples involved in KEGG pathways; n is the number of differentially expressed gene samples; m is the number of gene samples in one pathway; and k is the frequency of overlapping genes in all pathways. FDR\<0.01 was set as the threshold.

Identification of potentially interacting pathways
--------------------------------------------------

In order to explore potential synergistic relationships between BCa-affected pathways, we constructed the pathway network in which nodes represent pathways and edges represent nonrandom synergistic relationships (crosstalk interactions). The network was built using Cytoscape ([@b15-mmr-10-04-1746]). The crosstalk among pathways was then investigated by calculating the Jaccard index (Ji), similarly to a previous study ([@b16-mmr-10-04-1746]). The Ji is defined as follows:
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In this formula, \#intersection (path A, path B) represents the overlapping number of genes between pathway A and B, and \#union (path A, path B) represents the sum of genes in pathway A and B. All pathway pairs were grouped together to construct the network. Pathways that showed Ji≥0.01 and shared at least one DEG were selected.

Results
=======

Identification of DEGs
----------------------

Based on t-tests and a threshold FDR from multiple testing correction \<0.05, we identified 12,105 DEGs, 5,239 upregulated and 6,866 downregulated.

KEGG pathway enrichment analysis
--------------------------------

In order to gain further insights into the biological functions of the identified DEGs, we used a hypergeometric distribution test to identify the significantly enriched pathways related to BCa. Using a threshold FDR\<0.05, we found that upregulated DGEs are significantly enriched for 7 pathways ([Table I](#tI-mmr-10-04-1746){ref-type="table"}), while downregulated DGEs are significantly enriched for 47 pathways ([Table II](#tII-mmr-10-04-1746){ref-type="table"}).

Identification of interacting pathways of DGEs
----------------------------------------------

In order to systematically analyze the DEG functions, we used a Jaccard model to construct and identify the interactions between the BCa-affected pathways. We selected the pathways that showed Ji ≥ 0.01 and shared at least one DGE, and thus identified, from 172 pathway pairs, a total of 44 pathways that were considered good candidates for a crosstalk interaction ([Fig. 1](#f1-mmr-10-04-1746){ref-type="fig"}). Among these, a number of pathways relate to functional disorders and could thus be relevant to BCa.

Exploring the mechanisms underlying BCa through KEGG pathways
-------------------------------------------------------------

To investigate the mechanism underlying the BCa disorder, we focused on the immune- and inflammation-related pathways identified within the network of interacting pathways. These included chemokine signaling, complement and coagulation cascades, antigen processing and presentation pathways, natural killer cell-mediated cytotoxicity, T- and B-cell receptor signaling pathways, and the intestinal immune network for IgA production. Furthermore, in order to assess the role of immune responses in the development of cancer, we focused on the B- and T-cell receptor signaling pathways. We found that the B-cell receptor signaling pathway is downregulated in BCa, involving 36 DGEs ([Fig. 2](#f2-mmr-10-04-1746){ref-type="fig"}). The T-cell receptor signaling pathway is also downregulated, and contains 46 DGEs ([Fig. 3](#f3-mmr-10-04-1746){ref-type="fig"}).

Discussion
==========

BCa, which is pathologically diagnosed as transitional or urothelial carcinoma, is the only known solid tumor besides melanoma. Detection and treatment of BCa remain a challenge. Therefore, there is an urgent need to explore the mechanisms involved in BCa and develop an effective preventive strategy for this disorder. In the present study, we first identified DEGs by comparing mRNA expression profiling data (downlooaded from the GEO database) between cancer and control samples and then applied a hypergeometric distribution test to identify the significantly enriched pathways these DEGs are involved in. Furthermore, we constructed a network of the relevant pathways and assessed their potential interactions.

The KEGG pathway enrichment analysis showed that the upregulated DEGs are related to 7 pathways. Among these, the most significantly enriched is the cell-cycle regulation pathway, which is a signal transduction cascade triggered in response to the detection of DNA damage ([@b17-mmr-10-04-1746]), and which has been demonstrated to relate to the development of BCa. It has been demonstrated that cell-cycle regulatory pathways function as checkpoints that control the order and timing of cell- cycle transitions to ensure the fidelity of critical events, such as DNA replication and chromosome segregation ([@b18-mmr-10-04-1746]). Cells may be arrested at any phase of the cycle, temporarily halting the cell cycle and allowing DNA repair to be completed. Loss and/or perturbation of cell-cycle control checkpoints results in genomic instability and is a hallmark of cancer, as evidenced by the common association of polymorphisms/inactivation of cell-cycle control genes such as p53, p16 and Rb1, with various types of cancer ([@b19-mmr-10-04-1746],[@b20-mmr-10-04-1746]). Other pathways that were found as significantly enriched among upregulated DEGs were: those involved in cell proliferation, which is controlled by proteins that maintain the synchrony of cell growth, DNA synthesis, mitosis and cell division ([@b21-mmr-10-04-1746],[@b22-mmr-10-04-1746]); base excision repair, which is related to DNA repair mechanisms; and lysine degradation, which is involved in a wide range of metabolic disorders.

The downregulated DEGs were found as involved in 47 significantly enriched pathways, mainly including cell transfer-related pathways, such as: cell adhesion molecules and focal adhesion; cell growth-related pathways, such as WNT, transforming growth factor-β (TGF-β), mitogen-activated protein kinase (MAPK) and calcium signaling pathways; and cancer-related immune and inflammation pathways, such as the T-/B- cell receptor and the chemokine signaling pathways. Epidemiological studies have estimated that underlying infections and inflammatory responses are linked to 15--20% of cancer-related deaths worldwide ([@b23-mmr-10-04-1746]). The intrinsic immune pathway is activated by genetic events that cause neoplasia. Cancer cells produce inflammatory mediators, thereby generating an inflammatory microenvironment in the tumor.

To explore the potentially synergistic interactions among the BCa-affected pathways, we constructed a network based on significantly enriched pathways and Ji calculations. The crosstalk interactions revealed in this network indicated that cancer incidence relates to alterations in multiple processes, including environmental and genetic information processing, metabolism, organismal systems, and certain human diseases. These processes may synergistically contribute to the regulation and progression of BCa.

To further reveal the mechanisms underlying the BCa disorder, we focused on immune- and inflammation-related pathways. Our analysis indicated that natural killer cell-mediated cytotoxicity and the B- and T-cell receptor signaling pathways are associated with the formation of bladder tumors and may participate in the development of BCa. Numerous studies have demonstrated that structures on the transformed cell (either expressed as a result of the transformation process itself or induced by the ongoing but limited inflammatory response) are recognized by infiltrating lymphocytes such as natural killer T-, natural killer or γδ T-cells, which are then stimulated to produce interferon-γ (IFN-γ) ([@b24-mmr-10-04-1746],[@b26-mmr-10-04-1746]). The IFN-γ that is initially produced may induce a limited amount of tumor death through antiproliferative ([@b27-mmr-10-04-1746]) and apoptotic mechanisms. A previous study demonstrated that the bacillus Calmette-Guerin (BCG) vaccine plays an important role in the maturation of dendritic cells (DCs) by signaling through different Toll-like receptors, as indicated by upregulation of the DC maturation marker CD83 ([@b28-mmr-10-04-1746]) and secretion of inflammatory cytokines such as interleukin (IL)-12, IFN-γ and tumor necrosis factor-α, suggesting a predominant involvement of the T-helper 1 lymphocyte subpopulation in inflammation. Tumor-specific CD4 and CD8 T-cells home to the tumor along a chemokine gradient where they recognize and destroy tumor cells expressing distinct tumor antigens. Furthermore, natural killer, lymphocyte-activated and BCG-activated killer cells and macrophages can kill bladder tumor cells *in vitro* ([@b29-mmr-10-04-1746]).

Activator protein 1 (AP-1), involved in cellular proliferation, transformation and death ([@b30-mmr-10-04-1746]), is a dimeric complex that contains members of the JUN, FOS, ATF and MAF protein families. AP-1 proteins are primarily considered to be oncogenic, but recent studies have shown that they can also have a tumor-suppressor activity ([@b31-mmr-10-04-1746]). It was further demonstrated that members of the AP-1 complex and ATF2 synergistically contribute to tumorigenesis ([@b32-mmr-10-04-1746]). Nuclear factor of activated T-cells (NFAT) is a protein family first identified more than two decades ago as a major stimulation-responsive DNA-binding factor and transcriptional regulator family in T cells. It is now established that NFAT proteins play important roles in additional types of immune cells and regulate numerous developmental processes in vertebrates. Dysregulation of these processes can lead to malignant growth and cancer ([@b33-mmr-10-04-1746]). The nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) is activated by a variety of cancer-promoting agents. The reciprocal activation between NF-κB and inflammatory cytokines renders NF-κB an important factor for inflammation-associated cancer development. Both the constitutive and anticancer therapeutic agent-induced NF-κB activation blocks the anticancer activities of the therapeutic agents. Elucidating the roles of NF-κB in cancer facilitates the development of approaches for cancer prevention and therapy ([@b34-mmr-10-04-1746]). A recent study showed that IL-20 promotes the migration of BCa cells by inducing ERK-mediated matrix metalloproteinase-9 expression, leading to the activation of NF-κB through the upregulation of p21 (WAF1) ([@b35-mmr-10-04-1746]). IL-10 is the most important cytokine with anti-inflammatory properties besides TGF-β and IL-35. It is produced by activated immune cells and regulates the functions of numerous and distinct types of immune cells. In addition, IL-10 plays an important role in the biology of B and T cells. The physiological relevance of this cytokine lies in the prevention and limitation of specific and unspecific immune reactions and, consequently, of tissue damage ([@b36-mmr-10-04-1746]). One study revealed the inhibitory role of IL-10 in BCG-induced macrophage cytotoxicity, suggesting that blocking IL-10 may potentially enhance the effect of BCG in the treatment of BCa patients ([@b37-mmr-10-04-1746]).

Overall, the present study presented a comprehensive bioinformatic analysis of genes and pathways that may be involved in the progression of BCa. Our results on immune- and inflammation-related pathways affected by BCa may prove helpful in the development of a new strategy to treat BCa in combination with medical therapy. Considering the increasing public availability of genomic data, we argue that our approach will constitute an attractive strategy for identifying disease-related pathways and interactions in numerous future studies. However, further experimental studies are needed to reveal the molecular mechanisms underlying BCa-associated processes.

![The network of the 44 PCa-affected pathways and interactions between these. Bottle green boxes, cellular process pathways; yellow, environmental information processing pathways; red, human disease-related pathways; green, organismal systems pathways; orange, metabolic pathways; and blue, information processing pathways.](MMR-10-04-1746-g02){#f1-mmr-10-04-1746}

![Differentially expressed genes (DEGs) in the B-cell receptor signaling pathway. Pink boxes, DEGs; green, non differentially expressed genes. Source: Kyoto Encyclopedia of Genes and Genomes.](MMR-10-04-1746-g03){#f2-mmr-10-04-1746}

![Differentially expressed genes (DEGs) in the T-cell receptor signaling pathway. Pink boxes, DEGs; green, non-differentially expressed genes. Source: Kyoto Encyclopedia of Genes and Genomes.](MMR-10-04-1746-g04){#f3-mmr-10-04-1746}

###### 

Significantly enriched pathways among the upregulated differentially expressed genes (DEGs).

  KEGG id.   Pathway name                        Genes   DEGs   P-value    BH[a](#tfn1-mmr-10-04-1746){ref-type="table-fn"}
  ---------- ----------------------------------- ------- ------ ---------- --------------------------------------------------
  hsa04110   Cell cycle                          128     62     5.11E-08   1.19E-05
  hsa05322   Systemic lupus erythematosus        138     57     7.80E-05   9.05E-03
  hsa03008   Ribosome biogenesis in eukaryotes   84      38     1.30E-04   1.01E-02
  hsa03030   DNA replication                     36      20     1.83E-04   1.06E-02
  hsa03410   Base excision repair                34      19     2.39E-04   1.11E-02
  hsa00310   Lysine degradation                  44      22     6.41E-04   2.48E-02
  hsa03013   RNA transport                       153     58     9.74E-04   3.23E-02

q-value from Benjamini and Hochberg multiple testing connection.

KEGG, Kyoto Encyclopedia of Genes and Genomes.

###### 

Significantly enriched pathways among the downregulated differentially expressed genes (DEGs).

  KEGG id.   Pathway name                                      Genes   DEGs   P-value    BH[a](#tfn3-mmr-10-04-1746){ref-type="table-fn"}
  ---------- ------------------------------------------------- ------- ------ ---------- --------------------------------------------------
  hsa04640   Hematopoietic cell lineage                        88      49     2.93E-08   6.79E-06
  hsa05330   Allograft rejection                               39      27     8.31E-08   9.64E-06
  hsa05416   Viral myocarditis                                 72      41     1.73E-07   1.33E-05
  hsa05150   *Staphylococcus aureus* infection                 56      34     2.39E-07   1.39E-05
  hsa05332   Graft-versus-host disease                         43      28     3.51E-07   1.63E-05
  hsa04514   Cell adhesion molecules                           136     65     4.32E-07   1.67E-05
  hsa04510   Focal adhesion                                    200     87     9.64E-07   2.83E-05
  hsa04612   Antigen processing and presentation               78      42     9.76E-07   2.83E-05
  hsa05323   Rheumatoid arthritis                              92      47     1.66E-06   4.29E-05
  hsa04940   Type I diabetes mellitus                          45      27     5.81E-06   1.35E-04
  hsa05145   Toxoplasmosis                                     133     60     1.22E-05   2.58E-04
  hsa04672   Intestinal immune network for IgA production      49      28     1.44E-05   2.79E-04
  hsa05140   Leishmaniasis                                     73      36     7.18E-05   1.28E-03
  hsa05310   Asthma                                            31      19     9.62E-05   1.59E-03
  hsa05144   Malaria                                           51      27     1.25E-04   1.93E-03
  hsa04662   B-cell receptor signaling pathway                 75      36     1.46E-04   2.11E-03
  hsa00280   Valine, leucine and isoleucine degradation        44      24     1.61E-04   2.19E-03
  hsa05146   Amoebiasis                                        106     47     1.76E-04   2.26E-03
  hsa04145   Phagosome                                         156     64     2.16E-04   2.64E-03
  hsa03010   Ribosome                                          92      41     3.92E-04   4.29E-03
  hsa04020   Calcium signaling pathway                         177     70     4.07E-04   4.29E-03
  hsa04062   Chemokine signaling pathway                       189     74     4.01E-04   4.29E-03
  hsa05320   Autoimmune thyroid disease                        54      27     4.26E-04   4.30E-03
  hsa05142   Chagas disease (American trypanosomiasis)         104     45     4.66E-04   4.51E-03
  hsa04512   ECM-receptor interaction                          85      38     5.87E-04   5.45E-03
  hsa04660   T-cell receptor signaling pathway                 108     46     6.17E-04   5.51E-03
  hsa00640   Propanoate metabolism                             32      18     6.49E-04   5.58E-03
  hsa04610   Complement and coagulation cascades               69      32     7.21E-04   5.97E-03
  hsa05020   Prion diseases                                    35      19     8.35E-04   6.46E-03
  hsa05340   Primary immunodeficiency                          35      19     8.35E-04   6.46E-03
  hsa05200   Pathways in cancer                                327     116    1.13E-03   8.47E-03
  hsa05412   Arrhythmogenic right ventricular cardiomyopathy   74      33     1.39E-03   1.01E-02
  hsa04060   Cytokine-cytokine receptor interaction            275     99     1.50E-03   1.05E-02
  hsa04310   WNT signaling pathway                             151     59     1.59E-03   1.08E-02
  hsa04810   Regulation of actin cytoskeleton                  214     79     1.99E-03   1.32E-02
  hsa05410   Hypertrophic cardiomyopathy                       87      37     2.10E-03   1.35E-02
  hsa04350   TGF-β signaling pathway                           85      36     2.61E-03   1.59E-02
  hsa05143   African trypanosomiasis                           35      18     2.56E-03   1.59E-02
  hsa04380   Osteoclast differentiation                        128     50     3.52E-03   2.09E-02
  hsa05414   Dilated cardiomyopathy                            90      37     4.22E-03   2.45E-02
  hsa04010   MAPK signaling pathway                            272     95     5.19E-03   2.86E-02
  hsa05222   Small cell lung cancer                            85      35     5.15E-03   2.86E-02
  hsa04650   Natural killer cell mediated cytotoxicity         140     53     5.78E-03   3.12E-02
  hsa05162   Measles                                           134     51     5.94E-03   3.13E-02
  hsa04916   Melanogenesis                                     101     40     6.49E-03   3.35E-02
  hsa00410   β-alanine metabolism                              27      14     6.91E-03   3.48E-02
  hsa00604   Glycosphingolipid biosynthesis-ganglio series     15      9      8.93E-03   4.41E-02

q-value from Benjamini and Hochberg multiple testing connection.

KEGG, Kyoto Encyclopedia of Genes and Genomes; ECM, extracellular matrix; TGF-β, transforming growth factor-β; MAPK, mitogen-activated protein kinase.

[^1]: Contributed equally
